FDA Advisory Panel Recommends Novavax Vaccine for Use in the US
The U.S. Food and Drug Administration recommended an emergency use authorization for a COVID-19 vaccine from Novavax, Inc. on Tuesday, the second non-mRNA–based vaccine to be used in the U.S.
The FDA held an all-day Vaccines and Related Biological Products Advisory Committee meeting on June 7, and a panel of vaccine experts voted 21-0, with one abstention, in favor of the vaccine for those 18 and older.
Similar to flu vaccines, the Novavax shot uses recombinant proteins grown in cell cultures developed by the biotech company based in Gaithersburg, Maryland.
Global health experts believe EUA approval from the FDA for the Novavax COVID-19 vaccine could potentially help change the minds of people who are still vaccine hesitant in the United States based on concerns over the mRNA technology used in other vaccines.
Results from a February phase 3 clinical trial in the U.K. also show it is 83% effective against all COVID-19 infections, and 100% effective at combating severe disease.
Alexa can be reached at [email protected]